GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kolon Life Science Inc (XKRX:102940) » Definitions » Price-to-Owner-Earnings

Kolon Life Science (XKRX:102940) Price-to-Owner-Earnings : (As of Jun. 16, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Kolon Life Science Price-to-Owner-Earnings?

As of today (2024-06-16), Kolon Life Science's share price is ₩22000.00. Kolon Life Science does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Kolon Life Science's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Kolon Life Science was 213.32. The lowest was 183.64. And the median was 187.63.


XKRX:102940's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 24.87
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-16), Kolon Life Science's share price is ₩22000.00. Kolon Life Science's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-2,683.00. Therefore, Kolon Life Science's PE Ratio for today is At Loss.

As of today (2024-06-16), Kolon Life Science's share price is ₩22000.00. Kolon Life Science's EPS without NRI for the trailing twelve months (TTM) ended in was ₩-2,498.78. Therefore, Kolon Life Science's PE Ratio without NRI for today is At Loss.

During the past 13 years, Kolon Life Science's highest PE Ratio without NRI was 2448.17. The lowest was 0.00. And the median was 94.30.


Kolon Life Science Price-to-Owner-Earnings Historical Data

The historical data trend for Kolon Life Science's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kolon Life Science Price-to-Owner-Earnings Chart

Kolon Life Science Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Kolon Life Science Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kolon Life Science's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Kolon Life Science's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kolon Life Science's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kolon Life Science's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Kolon Life Science's Price-to-Owner-Earnings falls into.



Kolon Life Science Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Kolon Life Science's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=22000.00/-4029.64
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kolon Life Science  (XKRX:102940) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Kolon Life Science Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Kolon Life Science's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Kolon Life Science (XKRX:102940) Business Description

Traded in Other Exchanges
N/A
Address
110, Magokdong-ro, Gangseo-gu, One & Only Tower, Seoul, KOR
Kolon Life Science Inc develops, manufactures and sells Biopharmaceuticals, Active pharmaceutical ingredients, Antimicrobials and Water solutions. Its products include Invossa, KLS-1010, KLS-2020, Azilsartan, Besfloc etc. The company has manufacturing facilities in Chungju, Eumsung and Kimchun.

Kolon Life Science (XKRX:102940) Headlines

No Headlines